Alkaloid AD Skopje (ALK)

Executive Summary

Alkaloid AD Skopje, founded in 1936, is a long-established pharmaceutical company based in North Macedonia. It operates as an integrated developer, manufacturer, and marketer of a broad portfolio including generic prescription drugs, over-the-counter (OTC) products, and cosmetics. The company serves both domestic and international markets across Southeast Europe and beyond. With a valuation of approximately $4.7 billion, Alkaloid has a strong regional presence and a solid track record of over 80 years in the industry. The company's business model is vertically integrated, covering everything from research and development to production and distribution, which provides operational efficiencies and cost advantages. While the company is private, its financial stability and market position in generic pharmaceuticals suggest a resilient business model. However, limited public information and lack of recent pipeline disclosures introduce uncertainty regarding near-term growth catalysts. Alkaloid's focus on generic drugs positions it well in cost-sensitive healthcare markets, but future growth will depend on successful product launches, regulatory approvals, and geographic expansion.

Upcoming Catalysts (preview)

• Q2 2026Launch of new generic products in Southeast Europe60% success
• Q3 2026Expansion into Western European markets via partnerships or acquisitions40% success
• Q1 2026Regulatory approval of key abbreviated new drug applications (ANDAs)55% success